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Innovations
Genta Incorporated
Gallium Therapeutics: Take Two
preted that to mean it was probably Gallium is reversibly absorbed in
low levels into bone. It inhibits bonehaving a direct effect on bone.” This
was proved and became the basis loss by interfering with the action of
About 20 years ago, researchers at
Memorial Sloan-Kettering Cancer
Center began publishing a series of
papers describing the therapeutic for several patents. The develop- normal bone cells called osteoclasts
that degrade bone by secreting acidbenefits of gallium nitrate in the ment focus then branched to include
study of bone-sparing therapy intreatment of lymphoma and cancer- onto bone surface. As the osteoclast
secretes acid, small amounts of bone-related hypercalcemia. What fol- cancer patients.
IV gallium nitrate (Ganite) didlowed was a circuitous path from bound gallium are liberated from the
dissolved bone. The gallium thenFDA approval, a brief stint on the make it to market in 1991 for hyper-
calcemia therapy but was quicklymarket in the early 1990s for hyper- paralyzes the acid-producing pro-
ton pump of the osteoclasts. “Thecalcemia, then a demise into thera- displaced by the big boys of bone
metabolism therapy, the bisphos-peutic oblivion. Enter Raymond P. osteoclast doesn’t die,” says War-
rell, “it simply can’t dissolve boneWarrell, Jr., MD, one of the original phonates, including Didronel (eti-
dronate) and Aredia (pamidronate).MSKCC gallium nitrate researchers, due to the presence of gallium inhib-
iting that acid-producing pump.”and now Chairman and CEO of Eventually, Ganite was removed
from the market, with rights re-Berkeley Heights, New Jersey- IV Ganite for Hypercalcemia
and NHLbased Genta Incorporated. Warrell verting back to MSKCC.
and colleagues are breathing new Genta licensed the Ganite NDA and
IND in 2000. “We intend to follow alife into the old IV gallium formula-
tion—known as Ganite—as well as two-track path with Ganite,” says“The big advantage ofdeveloping a new oral product, all Warrell. They hope to relaunch the
gallium in cancer treat-for treatment of cancer and cancer- drug for its currently approved indi-
cation, hypercalcemia, but Warrellrelated bone disorders. ment is that it does not
Genta was founded in 1988 as a admits that market for first-line ther-suppress bone marrow orspin-off from the diagnostics com- apy is already well served by Novartis’
cause a drop in whitepany Gen-Probe. It was founded on Aredia (generic since December 2001)
and now Zometa (zoledronic acid),the antisense technology behind its blood or platelet counts.
lead agent, Genasense, an anti-Bcl-2 approved in 2002.As a result, we’re able todrug now in several phase III clinical Clearly the larger opportunity for
treat patients with lym-trials. Currently, about 90 employ- Ganite is to track back into the anti-
cancer indications. Toward that end,ees work on four main technology phoma who may have low
programs, “but our unifying program Genta is conducting a multicenterblood counts and cannotis not technology,” says Warrell. “In- phase IIB trial now for NHL. The trial
receive conventional ther-stead it’s market based, focusing was recently launched at the Medi-
cal College of Wisconsin under theon oncology.” apy.” — Christopher R.
Long Walk in the Desert direction of Christopher R. Chitambar,Chitambar, MDThe gallium nitrate story dates back MD. The drug is targeted for treat-
to the 1970s, when NCI researchers ment in approximately 40 myelosup-
discovered anticancer activity in pressed patients who have relapsed
several elements in group 111A from on conventional therapy.
Gallium Inhibits Bonethe periodic table of elements, which Nonmyelosuppressive
Resorptionincludes gallium. Gallium was found “The big advantage of gallium in
Under normal metabolic circum-to be the most active, least toxic, cancer treatment is that it does not
stances, bone generally forms andand the only element with efficacy suppress bone marrow or cause a
breaks down in equilibrium, a pro-when given at a site remote from drop in white blood or platelet
cess called bone remodeling. But inthe tumor. counts,” says Chitambar, who has
cancer and certain other metabolicIn the early 1980s, Warrell and col- been studying gallium therapeutics
bone disorders, bone loss is accel-leagues demonstrated good activity for more than 20 years. “As a result,
we’re able to treat patients with lym-with gallium nitrate against non- erated. For example, in hypercalce-
mia, a life-threatening disorder af-Hodgkin’s lymphoma (NHL). “But we phoma who may have low blood
counts and cannot receive conven-noticed an interesting side effect in fecting about 10%–20% of people
with cancer, bone loss is so severeour anticancer studies with gallium,” tional therapy.”
At the same time Warrell was pub-Warrell recalls. Calcium levels in that the kidney becomes over-
whelmed in its effort to remove ex-blood and urine began dropping in lishing papers at MSKCC showing
IV gallium was active in lymphoma,gallium-treated patients. “We inter- cess calcium.
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then bladder cancer, Chitambar be- eloma cells, you may prevent the the West—and Chitambar is famil-
iar with both gallium ventures—gan studying gallium’s transport dissolution of bone,” suggests War-
rell. This is the general idea appliedmechanism and how it inhibits can- researchers are eager to investigate
an oral formulation. “The pharmaco-cer-cell growth. He found that gal- to other cancers, like breast and
lung cancers, where bone metasta-lium binds to transferrin (a protein kinetics and side effects are proba-
bly going to be different with an oralthat transports iron) fairly strongly ses are a common, complicating
problem. “These people usuallywhen it enters the circulation. The drug,” says Chitambar, “It will first
need to be absorbed from the gut,gallium-transferrin complexes at- don’t die from their bone metasta-
ses, but their fractures give them lotstach themselves to the transferrin transferred to the circulation to bind
to transferrin, and then home in onreceptor, found in high levels on lym- of pain and reduced mobility,” says
Warrell of the quality of life benefitphoma cells. “This is a real benefit transferrin receptor-bearing cells.”
He hopes that in this way an oralbecause you’re getting the metal di- he hopes oral gallium can deliver.
IV Aredia, the most popular therapyrectly to the target,” he says. Blad- formulation may get to its target in
a more physiologic way, “similar toder cancer cells also have transferrin used for bone metastases treatment
with more than $750 million in annualreceptors. “We showed gallium tar- other metals such as iron.” Chi-
tambar guesses that to be effectivegets cellular iron metabolism and in- sales, has already validated this idea
over the last 10 years.hibits ribonucleotide reductase, an any oral gallium will require daily or
near-daily administration for severaliron-dependent enzyme responsible A Titan to Compete With
Genta shares the gallium therapeu-for synthesis of deoxynucleotide weeks. Whether in IV form or oral,
or complexed as a salt or sugar, gal-precursors, dNTPs, prior to DNA tics stage with South San Francisco,
California-based Titan Pharmaceuti-synthesis,” says Chitambar. “Iron is lium appears to be a welcome ther-
apy with a ready and patiently wait-critical for that enzyme activity, and cals. “Both groups, Genta and Titan,
are working on oral gallium formula-gallium either displaces the iron or ing market in the cancer-treatment
arena.it blocks the utilization of iron by tions, and it is a very exciting devel-
opment,” says Chitambar. “It will bethis enzyme.”
Chemistry & Biology invites your“Ganite is fairly well tolerated, a major stride.”
comments on this topic. Pleasethough hydration is a must,” he says. Titan, formed in 1992, is develop-
write to the editors at chembiol@In a previous NHL study with gallium ing its own oral gallium compound,
cell.com.nitrate, he found that about half of gallium maltolate, discovered by
Lawrence Bernstein at Stanford Uni-14 heavily pretreated patients had Alice A. McCarthy is a freelance science
a good response; 4 of whom had versity, who then formed GeoMed, writer based in Magnolia, MA (alice@
alicemccarthy.com).“impressive” responses. “I also found Inc. to develop it. “We licensed it
after it had proven good oral bio-that when patients respond, they
tend to respond rapidly,” says Chi- availability and safety,” says Frank
H. Valone, MD, Executive Vice Presi-tambar. “Sometimes even during
treatment the masses will start dent, Clinical Development and Regu-
latory Affairs at Titan. Similar to Genta,shrinking.”
Oral Formulation for Bone Titan’s focus is to develop an oral
gallium therapy for cancer and boneMetastases
Genta is also developing an oral gal- damage produced by cancer. The
company is now doing an expandedlium agent for prevention of bone
loss in patients whose disease has 30-patient phase I trial in prostate
and bladder cancers, myeloma, andmetastacized to bone. The presence
of cancer, either directly in the bone lymphoma. “We’ve found a dose
where we can achieve sustainedor remotely by the release of certain
stimulating factors, induces osteo- blood levels for therapeutic effi-
cacy,” says Valone, “and we haveclast overactivity. “This accelerated
activity breaks down bone very no known safety issues so far.”
“We think gallium will probably bequickly,” according to Warrell.
“We think we have a drug that is effective for prevention of bone pain
and fractures, much the way bis-superior in efficacy to any of the bis-
phosphonates that currently exist,” phosphonates are,” says Valone.
And like Warrell, Valone believes thesays Warrell. “It is essentially a new
chemical entity, but ionic gallium is oral formulation will be the key for
competing with the bisphospho-the active species,” he says. Genta
will clearly target comparative stud- nates in the bone metastases mar-
ket. “We aren’t limited in our abilityies against the Novartis drugs for the
bone metastases indication. to deliver gallium therapeutically
now,” he says. “In our case, theGenta may also target oral gallium
for treatment of myeloma, a malig- availability of the maltol complex
gives us a chance to readdress thenancy of the bone marrow. “If you
can make the bone environment utility of gallium.”
Whether it’s on the East Coast ormore hostile to the expansion of my-
